Using MRI to predict treatment success in lung cancer
Official title: Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer
Run by Yunnan Cancer Hospital · NCT06742021 · Data updated 2026-11-12
This study is testing if special MRI scans can help doctors better predict how well targeted and immunotherapy treatments will work for people with lung cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 195 (estimated) |
| Sponsor | Yunnan Cancer Hospital Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Kunming, Yunnan) |
| Status | Recruiting |
| Started | November 11, 2024 |
| Main results expected | July 31, 2026 |
| Study ends | July 31, 2026 |
| Registry record updated | December 19, 2024 |
| Trial ID | NCT06742021 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are lung cancer patients aged 18 to 75 with tumors larger than 2 cm.
✕Probably not a fit
Patients with MRI contraindications or those who cannot tolerate gadolinium contrast agents may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to improve the prediction of treatment efficacy for lung cancer patients undergoing targeted and immunotherapy. It utilizes dynamic contrast-enhanced MRI (DCE-MRI) images taken before and after the first treatment cycle, combined with clinical and pathological data, to assess how well these therapies work. By analyzing these images, the study seeks to provide more accurate predictions that could guide treatment decisions for patients with lung cancer.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment plans for lung cancer patients.
How similar studies have gone: While the use of MRI in treatment prediction is explored, this specific approach utilizing DCE-MRI in lung cancer is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Tumor size greater than 2 cm 2. Age between 18 and 75 years Exclusion Criteria: 1. Presence of MRI contraindications (e.g., metal implants, pacemaker implantation, etc.) 2. Allergy to gadolinium contrast agents 3. Lesions difficult to delineate on images due to conditions such as atelectasis or diffuse lesions
Where it's running
-
Yunnan Cancer Hospital
Kunming, Yunnan, China Recruiting
Study contacts
- Study coordinator: zhihui shi
- Email: 3332105746@qq.com
- Phone: 15087838660
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.